Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma with Positive Peritoneal Cytology
NCT03703089Phase 1Unknown
- Sponsor
- Benaroya Research Institute
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Benaroya Research Institute. Primary endpoint: Frequency of cytological conversion at 6 months. Status: unknown.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03703089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703089.